FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990993871> ?p ?o ?g. }

• W1990993871 endingPage "S19" @default.
• W1990993871 startingPage "S2" @default.
• W1990993871 abstract "The goal of endocrine therapy in breast cancer is to block the action of estrogen on the tumor cells either by inhibiting estrogen from binding to the specific estrogen receptor or by inhibiting its synthesis. Tamoxifen, a selective estrogen receptor modulator, is the standard endocrine treatment for hormone receptor-positive breast cancer, both in the adjuvant and metastatic settings. Tamoxifen inhibits the binding of estrogen to the receptor, resulting in inhibition of hormone action. However, as tamoxifen is also weakly estrogenic, it may not be optimally effective and increases the risk of endometrial cancer and stroke. Furthermore, patients may be refractory or may become resistant to tamoxifen treatment. Since aromatase inhibitors (AI) block the synthesis of estrogen and have no intrinsic estrogenic activity, they have the potential to be more effective than tamoxifen. Their different mechanism of action and chemical structures may also circumvent tamoxifen resistance. Consequently, AIs are currently being evaluated as an alternative to tamoxifen treatment. A preclinical model has recently been developed to compare the efficacy of AIs and antiestrogens in different treatment schemes and to assist in the design of clinical trials. Current studies with the MCF-7Ca xenograft model are exploring the effects of combination and sequential therapy on tumor growth. The efficacy of AIs in the treatment of hormone receptor-positive breast cancer was first demonstrated in five multicenter second-line trials enrolling several hundreds of postmenopausal patients with metastatic breast cancer who had failed tamoxifen treatment. More recently, anastrozole demonstrated efficacy at least equivalent to that of tamoxifen in first-line randomized, phase III clinical trials in postmenopausal women with hormone receptor-positive or unknown metastatic breast cancer, whereas letrozole demonstrated superiority. The steroidal AI exemestane is currently under evaluation. Letrozole is the only AI to have been studied in a randomized, phase III trial in the neoadjuvant setting. In this trial, more patients underwent breast-conserving surgery with letrozole than with tamoxifen. Smaller phase II studies also suggest that both anastrozole and exemestane are active in the neoadjuvant setting. Because neoadjuvant trials permit temporal sampling of breast tissue, substudies in the phase III trial with letrozole have examined the impact of such biomarkers as estrogen receptor, progesterone receptor and epidermal growth factor receptor family members, HER-1 and HER-2, on patient response. AIs are currently under evaluation in the adjuvant setting, and preliminary results of the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial have been reported. AIs have proven as safe as tamoxifen in trials in patients with metastatic breast cancer. Ongoing clinical trials in the adjuvant setting include companion studies of end-organ effects, particularly bone metabolism and lipid metabolism evaluations. Quality-of-life assessments are also parts of major clinical trials. A head-to-head quality-of-life assessment of anastrozole compared with letrozole demonstrated patient preference for letrozole. These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions" @default.
• W1990993871 created "2016-06-24" @default.
• W1990993871 creator A5018533808 @default.
• W1990993871 creator A5035383163 @default.
• W1990993871 creator A5071541231 @default.
• W1990993871 creator A5076095333 @default.
• W1990993871 date "2003-08-01" @default.
• W1990993871 modified "2023-10-18" @default.
• W1990993871 title "Challenges in the endocrine management of breast cancer" @default.
• W1990993871 cites W1453600927 @default.
• W1990993871 cites W1562190372 @default.
• W1990993871 cites W1821522531 @default.
• W1990993871 cites W1839333839 @default.
• W1990993871 cites W1909697168 @default.
• W1990993871 cites W1932574503 @default.
• W1990993871 cites W1934173384 @default.
• W1990993871 cites W1971835148 @default.
• W1990993871 cites W1975973972 @default.
• W1990993871 cites W1976393887 @default.
• W1990993871 cites W1978203969 @default.
• W1990993871 cites W1978228601 @default.
• W1990993871 cites W1979616889 @default.
• W1990993871 cites W1981700496 @default.
• W1990993871 cites W1992222754 @default.
• W1990993871 cites W2003566890 @default.
• W1990993871 cites W2009772542 @default.
• W1990993871 cites W2017227663 @default.
• W1990993871 cites W2036071320 @default.
• W1990993871 cites W2038901861 @default.
• W1990993871 cites W2042162210 @default.
• W1990993871 cites W2043652943 @default.
• W1990993871 cites W2052419035 @default.
• W1990993871 cites W2067456063 @default.
• W1990993871 cites W2068044367 @default.
• W1990993871 cites W2079286586 @default.
• W1990993871 cites W2088006738 @default.
• W1990993871 cites W2089247500 @default.
• W1990993871 cites W2090893404 @default.
• W1990993871 cites W2096840197 @default.
• W1990993871 cites W2100419426 @default.
• W1990993871 cites W2104540021 @default.
• W1990993871 cites W2104919541 @default.
• W1990993871 cites W2105913824 @default.
• W1990993871 cites W2109617076 @default.
• W1990993871 cites W2113077666 @default.
• W1990993871 cites W2114167623 @default.
• W1990993871 cites W2114406983 @default.
• W1990993871 cites W2128100826 @default.
• W1990993871 cites W2132846837 @default.
• W1990993871 cites W2133667885 @default.
• W1990993871 cites W2133764838 @default.
• W1990993871 cites W2139726760 @default.
• W1990993871 cites W2141647078 @default.
• W1990993871 cites W2145819414 @default.
• W1990993871 cites W2146049019 @default.
• W1990993871 cites W2153247110 @default.
• W1990993871 cites W2155481621 @default.
• W1990993871 cites W2160592191 @default.
• W1990993871 cites W2166631738 @default.
• W1990993871 cites W2171423946 @default.
• W1990993871 cites W2202169216 @default.
• W1990993871 cites W2242258808 @default.
• W1990993871 cites W2508460892 @default.
• W1990993871 cites W4252112751 @default.
• W1990993871 cites W4256389474 @default.
• W1990993871 cites W4300776185 @default.
• W1990993871 doi "https://doi.org/10.1016/s0960-9776(03)80158-3" @default.
• W1990993871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14659138" @default.
• W1990993871 hasPublicationYear "2003" @default.
• W1990993871 type Work @default.
• W1990993871 sameAs 1990993871 @default.
• W1990993871 citedByCount "39" @default.
• W1990993871 countsByYear W19909938712012 @default.
• W1990993871 countsByYear W19909938712013 @default.
• W1990993871 countsByYear W19909938712014 @default.
• W1990993871 countsByYear W19909938712015 @default.
• W1990993871 countsByYear W19909938712016 @default.
• W1990993871 crossrefType "journal-article" @default.
• W1990993871 hasAuthorship W1990993871A5018533808 @default.
• W1990993871 hasAuthorship W1990993871A5035383163 @default.
• W1990993871 hasAuthorship W1990993871A5071541231 @default.
• W1990993871 hasAuthorship W1990993871A5076095333 @default.
• W1990993871 hasConcept C121608353 @default.
• W1990993871 hasConcept C126322002 @default.
• W1990993871 hasConcept C134018914 @default.
• W1990993871 hasConcept C143998085 @default.
• W1990993871 hasConcept C2775930923 @default.
• W1990993871 hasConcept C2776166826 @default.
• W1990993871 hasConcept C2776215463 @default.
• W1990993871 hasConcept C2777164284 @default.
• W1990993871 hasConcept C2777176818 @default.
• W1990993871 hasConcept C2777944059 @default.
• W1990993871 hasConcept C46699223 @default.
• W1990993871 hasConcept C502942594 @default.
• W1990993871 hasConcept C530470458 @default.
• W1990993871 hasConcept C71315377 @default.
• W1990993871 hasConcept C71924100 @default.
• W1990993871 hasConcept C84606932 @default.

• next